<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Infection Immunity and Inflammation</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F6255370-95E5-4AB8-B013-978B1124F433"><gtr:id>F6255370-95E5-4AB8-B013-978B1124F433</gtr:id><gtr:firstName>Jacqueline</gtr:firstName><gtr:surname>Katz</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/905877C1-5AB0-42D2-82CF-1D9A116A983C"><gtr:id>905877C1-5AB0-42D2-82CF-1D9A116A983C</gtr:id><gtr:firstName>Giuseppe</gtr:firstName><gtr:surname>Del Giudice</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EBF97B0E-0FDD-400A-AF02-732CEE39912F"><gtr:id>EBF97B0E-0FDD-400A-AF02-732CEE39912F</gtr:id><gtr:firstName>Karl</gtr:firstName><gtr:surname>Nicholson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8E9F49FC-ACAD-47FD-85F9-AFC5FE2CEFBC"><gtr:id>8E9F49FC-ACAD-47FD-85F9-AFC5FE2CEFBC</gtr:id><gtr:firstName>Maria</gtr:firstName><gtr:surname>Zambon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CBAB80A6-A326-4E02-A3F3-C05704E163E5"><gtr:id>CBAB80A6-A326-4E02-A3F3-C05704E163E5</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:surname>Stephenson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700846"><gtr:id>1AC26AC1-FD5E-4511-8B64-8D29F809DC45</gtr:id><gtr:title>Evaluation of heterosubtypic immune responses in older people following seasonal or pandemic influenza vaccination</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700846</gtr:grantReference><gtr:abstractText>We are looking at testing influenza pandemic vaccines among healthy young and older people to improve protection against a possible influenza pandemic.
The spread of avian influenza H5N1 (bird flu) around the world has raised the real possibility of another influenza pandemic. Our unit has conducted evaluation of several vaccine candidates against H5 and H9 avian influenza in younger adults. Our studies, along with others, have found that it is usually necessary to give at least two doses of vaccine in order to produce effective protection. 
However when vaccines against avian influenza have been tested in older people it seems that some individuals react much better than expected and get good responses even after one dose of vaccine. 
We are planning to look at the immune systems of elderly people before and after being given avian influenza vaccines to see if we can find out why some people respond better. This might allow us to develop better vaccines that protect against different influenza strains</gtr:abstractText><gtr:technicalSummary>Influenza A is a respiratory infection of global importance and is responsible for frequent annual epidemics and infrequent pandemics. The emerging pan-epizoonotic of influenza A H5N1 in wild birds and poultry has been associated with over 250 human infections in several countries raising the fear that the next pandemic is imminent. Vaccination is the principal means of combating epidemic and pandemic influenza. In clinical trials among immunologically na?ve adults, at least two doses of conventional avian influenza H5 or H9 subunit vaccine are needed to induce moderate homologous antibody responses. Recent studies including older subjects have unexpectedly found that some people aged over 65 years have pre-vaccination neutralising antibodies to influenza H5 and H9 haemagglutinin. These subjects mount a robust antibody response to a single dose of H5 or H9 pandemic vaccine more consistent with responses seen following seasonal influenza vaccine suggesting that their immune systems are primed to at least some strains of avian influenza. Our clinical unit in Leicester has pioneered immmunogenicity assessment of avian influenza vaccines. Our aims, in collaboration with expert partners, Dr Jacqueline Katz (Centers for Disease Control) and Dr Del Giudice (Novartis Diagnostics), are to examine neutralising antibody responses to a range of human and non-human influenza viruses before and after seasonal and pandemic vaccination, identify haemagglutinin epitopes to which neutralising antibodies are directed, and evaluate cellular immune responses before and after pandemic H5 vaccination. Understanding of the basis of heterosubtypic neutralising antibody responses in humans may help steer the development of vaccines that induce broader immunity.</gtr:technicalSummary><gtr:fund><gtr:end>2013-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>564891</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Vaccines and Diagnostics</gtr:department><gtr:description>H5 Novartis</gtr:description><gtr:id>7A73EE80-CBCB-47FF-BBBB-DA2DD2605A09</gtr:id><gtr:impact>Laboratory analyses are completed and reports will be in progress</gtr:impact><gtr:outcomeId>azJpmuefSWy-1</gtr:outcomeId><gtr:partnerContribution>The MRC funded study has allowed us to conduct cell mediated immune measurements pre and post vaccination. The results have been discussed and reports are in preparation</gtr:partnerContribution><gtr:piContribution>we have provided pre and post vaccine clinical blood samples. novartis has performed cell mediated immune responses</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Pandemic influenza</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>4069FAFD-1CD0-4625-BD2B-0F933EA1FBFC</gtr:id><gtr:impact>Articles for Leicester mercury (local newspaper)
BBC TV news interviews - Panorama, BBC East Midlands News

none known</gtr:impact><gtr:outcomeId>pJCWGEXnWSL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0EF4D6A3-6544-4E4C-9BBE-0BB54F651306</gtr:id><gtr:title>Willingness of healthcare workers to accept voluntary stockpiled H5N1 vaccine in advance of pandemic activity.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bec628b81c50d32f8d46e0bab6dcc65f"><gtr:id>bec628b81c50d32f8d46e0bab6dcc65f</gtr:id><gtr:otherNames>Pareek M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>b5ye87MM3KY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0745D83F-C69A-4ED6-AC2B-67C987E8BE88</gtr:id><gtr:title>Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86db17d48a061ea731393c13cac237d5"><gtr:id>86db17d48a061ea731393c13cac237d5</gtr:id><gtr:otherNames>Stephenson I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>Gko3149UDsF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30511612-4A51-4689-B0F7-1002646DF4D7</gtr:id><gtr:title>Reproducibility of serologic assays for influenza virus A (H5N1).</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86db17d48a061ea731393c13cac237d5"><gtr:id>86db17d48a061ea731393c13cac237d5</gtr:id><gtr:otherNames>Stephenson I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>qpAHpF5s8wT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF1AA9FB-1D33-4560-9BE4-486AA96BD583</gtr:id><gtr:title>Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50c378eba22c88cfd0f801a9aab2cc92"><gtr:id>50c378eba22c88cfd0f801a9aab2cc92</gtr:id><gtr:otherNames>Clark TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>QnftCA1Rq7h</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82DCE366-3012-4DBD-8CB4-D05089EF8A2A</gtr:id><gtr:title>Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86db17d48a061ea731393c13cac237d5"><gtr:id>86db17d48a061ea731393c13cac237d5</gtr:id><gtr:otherNames>Stephenson I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>c7Lzfs8TEMX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>531B8D36-1281-4552-8A39-574B62237FE2</gtr:id><gtr:title>Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f9001ddbf9ba19f0c7b1567c9218a7c"><gtr:id>2f9001ddbf9ba19f0c7b1567c9218a7c</gtr:id><gtr:otherNames>Galli G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>cepcKZqQUcL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9D0A6E2-F59F-40C0-BF95-B98D9B1BE52D</gtr:id><gtr:title>Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6468842455fa05fd0c88fae893b7df67"><gtr:id>6468842455fa05fd0c88fae893b7df67</gtr:id><gtr:otherNames>Nicholson KG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>noRRgHvKmyX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D72ECDD6-2CC0-43AE-B3D7-E1B7F937B44A</gtr:id><gtr:title>Antiviral treatment and prevention of seasonal influenza: a comparative review of recommendations in the European Union.</gtr:title><gtr:parentPublicationTitle>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86db17d48a061ea731393c13cac237d5"><gtr:id>86db17d48a061ea731393c13cac237d5</gtr:id><gtr:otherNames>Stephenson I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1386-6532</gtr:issn><gtr:outcomeId>bz1ZsdeMGPK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>251D650B-1162-4D9F-A699-CC22CCBE7EC7</gtr:id><gtr:title>Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86db17d48a061ea731393c13cac237d5"><gtr:id>86db17d48a061ea731393c13cac237d5</gtr:id><gtr:otherNames>Stephenson I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>VVpwmaoNUJT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C712FC16-21AF-49C8-AB9F-D095C1F06061</gtr:id><gtr:title>Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86db17d48a061ea731393c13cac237d5"><gtr:id>86db17d48a061ea731393c13cac237d5</gtr:id><gtr:otherNames>Stephenson I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>N9dPakXMXix</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B408692-F362-4570-BE2E-45273ECE6B39</gtr:id><gtr:title>Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86db17d48a061ea731393c13cac237d5"><gtr:id>86db17d48a061ea731393c13cac237d5</gtr:id><gtr:otherNames>Stephenson I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>FMtTLfRHVvr</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700846</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>